GH Research PLC

Healthcare

NASDAQ:GHRS · NASDAQ Global Market

Market Cap $1.52B Beta 1.31 P/E (TTM) -23.8

$22.24 -0.18%

-$0.04 today

52W Low $11.32High $25.94

Vol 0.54M · Avg 0.23M

EPS (TTM) -$0.91Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+90.41%

Period High

$24.87

Period Low

$11.68

Latest

$22.24

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Nanobiotix S.A.

NASDAQ:NBTX

$1.78B

Tyra Biosciences, Inc.

NASDAQ:TYRA

$1.68B

Palvella Therapeutics, Inc.

NASDAQ:PVLA

$1.32B

Savara Inc.

NASDAQ:SVRA

$1.11B

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

$958.28M

Arbutus Biopharma Corporation

NASDAQ:ABUS

$883.98M

Kura Oncology, Inc.

NASDAQ:KURA

$853.03M

Rezolute, Inc.

NASDAQ:RZLT

$496.85M

ProKidney Corp.

NASDAQ:PROK

$262.25M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

$189.54M

What is the latest GHRS filing?

The latest filing shown is 6-K dated Jun 4, 2026.

How many recent filings does GHRS have?

Intrinsic Alpha currently shows 20 recent filings for GHRS.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.